Antimalarial drug discovery: Where next?

Future Medicinal Chemistry

Volumn 4, Issue 18, 2012, Pages 2233-2235

  Burrows, Jeremy N ^a  

^a Medicines for Malaria Venture   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; INSECTICIDE;

EDITORIAL; HUMAN; MALARIA; MONOTHERAPY; MOSQUITO; OOCYST; PLASMODIUM OVALE; PLASMODIUM VIVAX; PRIORITY JOURNAL; RISK; SPOROZOITE;

ANIMALS; ANTIMALARIALS; DRUG DISCOVERY; HUMANS; MALARIA; PLASMODIUM;

EID: 84871041813     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.189     Document Type: Editorial

References (17)

1. WHO. World Malaria Report. Geneva, Switzerland (2011).
2. Burrows JN, Leroy D, Lotharius J, Waterson D. Challenges in antimalarial drug discovery. Future Med. Chem. 3(11), 1401-1412 (2011
3. Delves M, Plouffe D, Scheurer C et al. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med. 9(2), e1001169 (2012).
4. White MT, Conteh L, Cibulskis R, Ghani AC. Costs and cost-effectiveness of malaria control interventions-a systematic review. Malar. J. 10, 337 (2011).
5. Alonso PL, Brown G, Arevalo-Herrera M et al. A research agenda for malaria eradication: drugs. PLoS Med. 8(1), e1000406 (2011).
6. Anthony MP, Burrows JN, Duparc S, Moehrle J, Wells TN. The global pipeline of new medicines for the control and elimination of malaria. Malar. J. 11, 316 (2012).
7. Gardner MJ, Hall N, Fung E et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419(6906), 498-511 (2002).
8. Rottmann M, McNamara C, Yeung BKS et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329(5996), 1175-1180 (2010).
9. Lucet IS, Tobin A, Drewry D, Wilks AF, Doerig C. Plasmodium kinases as targets for new-generation antimalarials. Future Med. Chem. 4(18), 2295-2310 (2012).
10. Gamo FJ, Sanz LM, Vidal J et al. Thousands of chemical starting points for antimalarial lead identification. Nature 465, 305-310 (2010).
11. Mahajan SS, Gut J, Rosenthal PJ, Renslo AR. Ferrous-iron dependent delivery of therapeutic agents to the malaria parasite. Future Med. Chem. 4(18), 2241-2249 (2012).
12. Bueno JM, Herreros E, Angulo-Barturen I et al. Exploration of 4(1H)-pyridones as a novel family of potent antimalarials inhibitors of the plasmodial cytochrome bc1. Future Med. Chem. 4(18), 2311-2323 (2012).
13. Dandapani S, Comer E, Duvall JR, Munoz B. Hits, leads and drugs against malaria through diversity-oriented synthesis. Future Med. Chem. 4(18), 2279-2294 (2012).
14. Chigorimbo-Murefu NTL, Njoroge M, Nzila A, Louw S, Masimirembwa C, Chibale K. Biotransformation and biocatalysis: roles and applications in the discovery of antimalarials. Future Med. Chem. 4(18), 2325-2336 (2012).
15. Paquet T, Gordon R, Waterson D, Witty MJ, Chibale K. Antimalarial aminothiazoles and aminopyridines from phenotypic whole cell screening of a SoftFocus library. Future Med. Chem. 4(18), 2265-2277 (2012).
16. Delves MJ. Plasmodium cell biology should inform strategies used in the development of antimalarial transmission-blocking drugs. Future Med. Chem. 4(18), 2251-2263 (2012).
17. Lucantoni L, Avery VM. Whole-cell in vitro screening for gametocytocidal compounds. Future Med. Chem. 4(18), 2337-2359 (2012).